Low power CMOS neurochemical biosensor application in an implantable intelligent neurotrophic factor delivery hybrid microsystem for Parkinson's

We have developed a low power neurotransmitter biosensor which can be applied in an implantable closed-loop CMOS neurotrophic factor delivery microsystem which by protecting the healthy neurons and restoring damaged ones can maintain therapeutic levels of chemical concentrations in the brain. The hybrid microsystem is composed of novel biosensor that can sense micromolar concentration of neurotransmitters (dopamine) and embedded negative feedback circuits that control the flow of pharmacological agents in micro fluidic channels. The focus of this manuscript is on sensing, control and decision making circuitry. It consists of a current conveyer, a low noise low power amplifier, an integrator and a comparator with offset cancelation. Circuit is fabricated in CMOS 0.18 um with low power consumption of 921 nW.

[1]  Pierre Payoux,et al.  Limitations of current Parkinson's disease therapy , 2003, Annals of neurology.

[2]  B. Davidson,et al.  Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy , 1997, Science.

[3]  C. Allison.  Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma. , 2007, Issues in emerging health technologies.

[4]  V. Mark,et al.  SUBTHALAMIC NUCLEUS AND ITS CONNECTIONS: ANATOMIC SUBSTRATE FOR THE NETWORK EFFECTS OF DEEP BRAIN STIMULATION , 2009, Neurology.

[5]  C. Tanner,et al.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.

[6]  Richard B. Brown,et al.  A low-voltage, chemical sensor interface for systems-on-chip: the fully-differential potentiostat , 2004, 2004 IEEE International Symposium on Circuits and Systems (IEEE Cat. No.04CH37512).

[7]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[8]  C. Marsden,et al.  Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. , 1976, Journal of neurology, neurosurgery, and psychiatry.

[9]  C. von Kalle,et al.  Murine Leukemia Induced by Retroviral Gene Marking , 2002, Science.

[10]  P. Llorca,et al.  Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? , 2007, Neurology.

[11]  Patrick Santens,et al.  Lateralized effects of subthalamic nucleus stimulation on different aspects of speech in Parkinson’s disease , 2003, Brain and Language.

[12]  N.V. Thakor,et al.  Integrated potentiostat for neurotransmitter sensing , 2005, IEEE Engineering in Medicine and Biology Magazine.

[13]  J. Bloch,et al.  Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons , 2004, Neurobiology of Disease.

[14]  T. Chen,et al.  A current-starved inverter-based differential amplifier design for ultra-low power applications , 2013, 2013 IEEE 4th Latin American Symposium on Circuits and Systems (LASCAS).

[15]  Jiri Janata,et al.  Principles of Chemical Sensors , 1989 .

[16]  P. Brundin,et al.  Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. , 2006, International journal of pharmaceutics.

[17]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[18]  R. Wightman,et al.  Detecting subsecond dopamine release with fast-scan cyclic voltammetry in vivo. , 2003, Clinical chemistry.

[19]  M. Poustinchi,et al.  Low power noise immune circuit for implantable CMOS neurochemical sensor applied in neural prosthetics , 2011, 2011 5th International IEEE/EMBS Conference on Neural Engineering.

[20]  K. Buck,et al.  L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective. , 2010, Drug discovery today.

[21]  T. Osaka,et al.  Electrochemical modification of active carbon fiber electrode and its application to double-layer capacitor , 1996 .

[22]  Kun-Woo Park,et al.  Protection of nigral neurons by GDNF-engineered marrow cell transplantation , 2001, Neuroscience Research.

[23]  E. Benarroch,et al.  Subthalamic nucleus and its connections , 2008, Neurology.

[24]  J. Mallet,et al.  Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease , 2006, Neurobiology of Disease.

[25]  J. Sladek,et al.  Dopamine cell replacement: Parkinson's disease. , 1990, Annual review of neuroscience.

[26]  R. Grondin,et al.  Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson’s disease , 1998, Journal of Neurology.

[27]  Yu-Sheng Lai,et al.  A novel OTA with dual bulk-driven input stage , 2009, 2009 IEEE International Symposium on Circuits and Systems.

[28]  A. Michael,et al.  Electrochemical Methods for Neuroscience , 2006 .

[29]  J. Benoit,et al.  Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. , 2004, Biomaterials.

[30]  R. Gross.  Deep brain stimulation in the treatment of neurological and psychiatric disease , 2004, Expert review of neurotherapeutics.

[31]  R. Barker,et al.  Parkinson's disease and growth factors - are they the answer? , 2009, Parkinsonism & related disorders.

[32]  T. Yasuhara,et al.  Gene therapy for Parkinson's disease. , 2009, Journal of neural transmission. Supplementum.